NEW YORK (GenomeWeb)

Rna Diagnostics, a Canadian molecular diagnostics company, recently commenced a clinical trial to validate an assay it plans to commercialize that can be used to guide breast cancer treatment.

The trial, called Breast Cancer Response Evaluation for Individualized Therapy (BREVITY), involves investigators from five countries and aims to enroll over 700 patients from 40 centers over the next two years.

The goal of the trial is to assess the ability of Rna Diagnostics’ RNA Disruption Assay (RDA) to determine, though a biomarker, which patients are responding to treatment for primary breast cancer. The company hopes the data from BREVITY will support the commercial launch of its test in North America and Europe.

According to CEO Jeremy Bridge-Cook, access the article click here